8 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
Follow Craniofacial Abnormalities: new trials by email Literature Review of Craniofacial Abnormalities trials Research Report on Craniofacial Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 7 | 2020-05-14 | 2025-11-04 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Rogaratinib - Squamous-cell Non-small Cell Lung Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 15 | 2019-07-25 | 2022-11-09 |
| Synaptic Plasticity and Cognitive Function in RASopathies Lovastatin, Lamotrigine - Impaired Synaptic Plasticity, Impaired Cognition | Phase 2 | Terminated | Technical University of Munich | 16 | 2019-03-22 | 2023-11-30 |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2011-08-01 | 2020-09-03 |
| Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome Metyrosine, Placebo - Velo-cardio-facial Syndrome, Psychosis | Phase 2 | Terminated | Bausch Health Americas, Inc. | 2 | 2010-06-01 | 2019-11-22 |
| Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome rhIGF-1/rhIGFBP-3 - Noonan Syndrome | Phase 2 | Terminated | Insmed Incorporated | 24 | 2007-03-30 |
Acrocephalosyndactylia (5) · Noonan Syndrome (2) · Carcinoma, Transitional Cell (1) · Cognition Disorders (1) · Colorectal Neoplasms (1) · DiGeorge Syndrome (1) · Neoplasm Metastasis (1) · Neurofibromatosis 1 (1) · Psychotic Disorders (1) · Stomach Neoplasms (1)
Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Musculoskeletal Abnormalities (8) · Musculoskeletal Diseases (8) · Bone Diseases (5) · Bone Diseases, Developmental (5) · Craniosynostoses (5) · Dysostoses (5) · Limb Deformities, Congenital (5) · Syndactyly (5) · Synostosis (5) · Neoplasms (4) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3)
pemigatinib (2) · Carboplatin (1) · Gemcitabine (1) · Irinotecan (1) · Lamotrigine (1) · Lovastatin (1) · Rogaratinib (1) · alpha-Methyltyrosine (1) · brivanib (1) · derazantinib (1) · pembrolizumab (1)
Incyte Corporation (2) · Basilea Pharmaceutica (1) · Bausch Health Americas, Inc. (1) · Insmed Incorporated (1) · M.D. Anderson Cancer Center (1) · Swiss Cancer Institute (1) · Technical University of Munich (1)
United States (6) · Germany (4) · France (3) · Italy (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Japan (2) · Poland (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1)
Alfredo Addeo, MD (1) · Kenneth Attie, MD (1) · Luis Feliz Vinas, MD (1) · Michael Overman, MD (1) · Peter Langmuir, MD (1) · Robert J Shprintzen, PhD (1)
2016 (1), 2018 (1), 2019 (1)